Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index; 127 of the 264 sources its claims cite were checked for support.

Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights

Open access

Abstract

Review of clinical and preclinical evidence for itraconazole as a repurposed anticancer drug.

Overview

CoChat Summary

TL;DR

This paper is a 2021–2025 literature review on itraconazole (ITZ) as a repurposed anticancer agent, summarizing its chemistry, mechanisms, delivery systems, and evidence across multiple cancers. The review argues that ITZ has the strongest support as a combination or adjuvant therapy rather than a stand-alone anticancer drug.

Key findings

  • The review identifies four main anticancer mechanisms for ITZ: autophagy induction, anti-angiogenesis, reversal of multidrug resistance, and Hedgehog (Hh) pathway inhibition.
  • ITZ has reported activity across many cancer models, including NSCLC, prostate cancer, basal cell carcinoma, gastric cancer, colon cancer, pancreatic cancer, breast cancer, cervical/ovarian cancer, esophageal cancer, melanoma, and hemangioma endothelial cells.
  • In advanced metastatic biliary tract cancer, combination oral ITZ solution produced a 57% response rate, with 2 complete responses and 14 partial responses after first-line chemotherapy.
  • In advanced NSCLC, adding ITZ to platinum-based chemotherapy improved overall response rate and progression-free survival, but did not improve overall survival.
  • In metastatic pancreatic cancer, a regimen including ITZ was given to 81 patients; 64% responded overall, median overall survival was 14.4 months, and median progression-free survival was 8.3 months.

Methods

  • Narrative review of recent literature, focusing on studies from 2021–2025 about ITZ as a cancer therapy strategy.
  • Literature search across Web of Science, Scopus, Google, PubMed, and Google Scholar using itraconazole-related anticancer keywords.
  • The paper synthesizes preclinical studies, clinical trials, and drug-delivery studies rather than reporting a single original experiment.

Limitations

  • The paper states that direct comparisons among drug-delivery systems are still scarce, and that a systematic assessment of encapsulation efficiency, release profile, bioavailability, toxicity, and anticancer activity is still needed.
  • The review states that ITZ’s specific molecular targets across cancer types remain unclear, despite evidence for pathway-level effects.
  • Evident from the text: many conclusions are based on preclinical models, small early-phase trials, or combination regimens, so the clinical evidence is uneven and often not definitive.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1039/d5ra09799a

Cites

107 of 108 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Content charts provided in this review.
Fig. 1 Content charts provided in this review.CC BY · PubMed Central
Scheme 1 [Itraconazole synthesis], reproduced from ref. 14 with permission from Elsevier, Tetrahedron, and ref. 13 with permission from Elsevier, Journal of Medicinal Chemistry, copyright 2026.
Scheme 1 [Itraconazole synthesis], reproduced from ref. 14 with permission from Elsevier, Tetrahedron, and ref. 13 with permission from Elsevier, Journal of Medicinal Chemistry, copyright 2026.CC BY · PubMed Central
Fig. 2 [Anticancer mechanisms of ITZ. (1) Autophagy induction: ITZ suppresses the AKT/mTOR pathway, promoting autophagic cell death and inhibiting glioblastoma cell growth, partly through altered cholesterol trafficking. (2) Anti-angiogenic activity: ITZ inhibits angiogenesis via AMPK activation and mTOR suppression, mediated by VDAC1 targeting and disruption of cholesterol transport through NPC1. (3) Reversal of multidrug resistance: ITZ inhibits CYP3A4 activity, contributing to reduced drug metabolism and enhanced chemosensitivity. (4) Hh pathway inhibition: ITZ blocks SMO and GLI signaling, leading to downregulation of oncogenic targets involved in proliferation, survival, angiogenesis, and drug resistance], reproduced from ref. 27 with permission from Elsevier, ACS Chemical Biology, and ref. 23 with permission from Elsevier, Journal of Advanced Research, copyright 2026.
Fig. 2 [Anticancer mechanisms of ITZ. (1) Autophagy induction: ITZ suppresses the AKT/mTOR pathway, promoting autophagic cell death and inhibiting glioblastoma cell growth, partly through altered cholesterol trafficking. (2) Anti-angiogenic activity: ITZ inhibits angiogenesis via AMPK activation and mTOR suppression, mediated by VDAC1 targeting and disruption of cholesterol transport through NPC1. (3) Reversal of multidrug resistance: ITZ inhibits CYP3A4 activity, contributing to reduced drug metabolism and enhanced chemosensitivity. (4) Hh pathway inhibition: ITZ blocks SMO and GLI signaling, leading to downregulation of oncogenic targets involved in proliferation, survival, angiogenesis, and drug resistance], reproduced from ref. 27 with permission from Elsevier, ACS Chemical Biology, and ref. 23 with permission from Elsevier, Journal of Advanced Research, copyright 2026.CC BY · PubMed Central
Fig. 3 Mechanism of action of Itraconazole in cancer therapy.
Fig. 3 Mechanism of action of Itraconazole in cancer therapy.CC BY · PubMed Central
Fig. 4 Comparative overview of itraconazole delivery systems.
Fig. 4 Comparative overview of itraconazole delivery systems.CC BY · PubMed Central
Fig. 5 The chemical structure of a number of derivatives was created and produced using ITZ, an inhibitor of the hedgehog signal channel.
Fig. 5 The chemical structure of a number of derivatives was created and produced using ITZ, an inhibitor of the hedgehog signal channel.CC BY · PubMed Central

Verification

Claims the paper makes

115 Valid · 5 Not valid · 122 Not checked · 19 Own results and interpretations

135 more claims · 61 with their cited sources checked

Create a free account to see all 261 claims and to verify the 18 references still open.

See all claims — free account
  • It may state two separate claims as one. 113
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 97 references

Research works printed but not linked: 13

  1. Pantziarka, 2016, Ecancermedicalscience, 10, 610
  2. Pantziarka, 2015, Ecancermedicalscience, 9, 521
  3. Alzahrani, 2020, Oxid. Med. Cell. Longev., 2020, 3028387
  4. Cucchi, 2012, J. Exp. Pharmacol., 173
  5. Tsubamoto, 2015, Anticancer Res., 35, 4923
  6. N. S.Reddy , R.Vijitha and K.Rao , Polymer electrolyte membranes for fuel cell and drug delivery applications , KROS Publications , Cuddapah, India , 2021 , pp. 95–134
  7. Kudi, 2024, Drug Dev. Ind. Pharm., 1
  8. Bonthala, 2024, Journal of Integrative Natural Science, 17, 141
  9. El-kammar, 2024, Egyptian Journal of Histology, 47, 389
  10. Lima, 2022, Front. Pharmacol, 13, 869461, 10.3389/fphar.2022.869461 · DOI · Paper page
  11. Huang, 2025, Expert Opin. Drug Saf., 23, 87
  12. Somchit, 2009, J. Toxicol., 2009, 912320
  13. Wagh, 2012, Int. Scholarly Res. Not., 2012, 653465

Metadata

Authors
Marzi, M., Ghasemian, A., Ghanbariasad, A., Nournia, E., & Zarenezhad, E.
Affiliations
Fasa University of Medical Sciences (IR)
Corresponding author
Zarenezhad, Elham
Venue
RSC Advances
Published
2026
Volume
16
Issue
28
Pages
25651-25674
ISSN
2046-2069 (ISSN-L)
OpenAlex
W7161145431
Cited by
0
References
97
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • RSC Advances (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
Fasa University of Medical Sciences
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Keywords
itraconazole, drug repurposing, anticancer agents, triazole antifungals, angiogenesis inhibition, signaling pathway modulation, drug synthesis, drug delivery systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights. https://app.cochat.ai/papers/10.1039/d5ra09799a
The paper
Marzi, M., Ghasemian, A., Ghanbariasad, A., Nournia, E., & Zarenezhad, E. (2026). Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights. RSC Advances. https://doi.org/10.1039/d5ra09799a

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.